A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Pal Sumanta K.; Tangen Catherine; Thompson Ian M. Jr.; Balzer-Haas Naomi; George Daniel J.; Heng Daniel Y. C.; Shuch Brian; Stein Mark; Tretiakova Maria; Humphrey Peter; Adeniran Adebowale; Narayan Vivek; Bjarnason Georg A.; Vaishampayan Ulka; Alva Ajjai; Zhang Tian; Cole Scott; Plets Melissa; Wright John; Lara Primo N. Jr.

首页> 外文期刊>The Lancet >A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

【24h】

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

机译：Sunitinib与Cabozatinib，Croizotinib和Savolitinib治疗晚期乳头状肾细胞癌的比较：随机，开放标签，第2期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, with the MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of patients with PRCC.

机译：背景MET（也称为肝细胞生长因子受体）信号是乳头状肾细胞癌（PRCC）的关键驱动因素。鉴于转移性PRCC目前尚无最佳治疗方法，我们旨在比较现有的治疗标准舒尼替尼与MET激酶抑制剂卡博扎尼、克唑替尼和萨沃利替尼对PRCC患者的治疗效果。

著录项

来源
《The Lancet》 |2021年第10275期|共9页
作者
Pal Sumanta K.; Tangen Catherine; Thompson Ian M. Jr.; Balzer-Haas Naomi; George Daniel J.; Heng Daniel Y. C.; Shuch Brian; Stein Mark; Tretiakova Maria; Humphrey Peter; Adeniran Adebowale; Narayan Vivek; Bjarnason Georg A.; Vaishampayan Ulka; Alva Ajjai; Zhang Tian; Cole Scott; Plets Melissa; Wright John; Lara Primo N. Jr.;
展开▼
作者单位

City Hope Comprehens Canc Ctr Duarte CA 91010 USA;

SWOG Stat &

Data Management Ctr Seattle WA USA;

CHRISTUS Santa Rosa Med Ctr Hosp San Antonio TX USA;

Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;

Duke Univ Med Ctr Dept Med Durham NC 27710 USA;

Tom Baker Canc Clin Calgary AB Canada;

Univ Calif Los Angeles Inst Urol Oncol Los Angeles CA USA;

Columbia Univ Dept Med New York NY USA;

Univ Washington Dept Pathol Seattle WA 98195 USA;

Yale Univ Dept Pathol New Haven CT USA;

Yale Univ Dept Pathol New Haven CT USA;

Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;

Sunnybrook Odette Canc Ctr Toronto ON Canada;

Wayne State Univ Dept Med Detroit MI 48202 USA;

Univ Michigan Dept Med Ann Arbor MI 48109 USA;

Duke Canc Res Inst Alliance Clin Trials Oncol Durham NC USA;

NRG Oncol Oklahoma Canc Specialists &

Res Inst Tulsa OK USA;

SWOG Stat &

Data Management Ctr Seattle WA USA;

NCI Canc Therapy Evaluat Program Invest Drug Branch Bethesda MD 20892 USA;

Univ Calif Davis Ctr Comprehens Canc Sacramento CA 95817 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma [J] . ZHAN Hai-lun, GAO Xin, PU Xiao-yong, 中华医学杂志（英文版） . 2012,第021期
2. Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label,phase Ⅰ dose escalation and dose expansion trial [J] . Yan Song, Jinwan Wang, Xiubao Ren, 中国癌症研究（英文版） . 2021,第001期
3. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [J] . Powles Thomas, Plimack Elizabeth R., Soulieres Denis, The lancet oncology . 2020,第12期

机译：Pembrolizumab Plus Axitinib与Sunitinib单疗法作为先进肾细胞癌的一线治疗（Keynote-426）：从随机，开放标签，第3阶段试验中的延伸后续行动
4. Pembrolizumab plus axitinib versus sunitinib monotherapy as firstline treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (vol 21, p1563, 2020) [J] . Powles T., Plimack E. R., Soulieres D. The lancet oncology . 2020,第12期

机译：PEMBROLIZUMAB PLUS AXITINIB与SUNITINIB单疗法为小型治疗晚期肾细胞癌（KEYNOTE-426）：从随机，开放标签，第3阶段试验（VOL 21，P1563,2020）的延伸后续行动
5. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial [J] . Rini Brian I., Stenzl Arnulf, Zdrojowy Romauld, The lancet oncology . 2016,第11期

机译：IMA901，一种多肽类癌症疫苗，加舒尼替尼与单独舒尼替尼比较，作为晚期或转移性肾细胞癌（IMPRINT）的一线治疗：一项多中心，开放标签，随机，对照，3期试验
6. New DCE-MRI parameters to quantify the vascular changes induced by sunitinib treatment in renal carcinoma tumors [C] . Al-Bashir Areen K., Hillman Gilda G., Li Meng, Middle East Conference on Biomedical Engineering . 2014

机译：新的DCE-MRI参数可量化舒尼替尼治疗在肾癌肿瘤中诱导的血管变化
7. Understanding the Attributes of Papillary Renal Cell Carcinoma subtypes: Molecular Analysis, Biomarker Discovery and Implications to Therapy [D] . Saleeb, Rola Magdy Yousef. 2018

机译：了解乳头状肾细胞癌亚型的属性：分子分析，生物标志物发现及其对治疗的意义
8. Open-label randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial [O] . Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, 2018

机译：开放标签随机多中心II期研究通过剂量给药方案（剂量修改或剂量中断）评估舒尼替尼在晚期或转移性肾细胞癌患者中的疗效和耐受性：SURF试验的研究方案
9. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial [O] . Robert J Motzer, Brian I Rini, David F McDermott, 2019

机译：Nivolumab Plus IpiLimumab与Sunitinib在初始肾细胞癌的一线治疗中：随机，控制，第3阶段试验的延长疗效和安全结果
10. Development of a Phase I/II Clinical Trial Using Sterotactic Body Radiation Therapy (SBRT) for the Treatment of Localized Prostate Carcinoma [R] . Timmerman, R. D. 2006

机译：利用立体定向放射治疗（sBRT）治疗局限性前列腺癌开展I / II期临床试验

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅